

Gesynta Pharma Announces Second Closing of Series B Now Totaling SEK 347m – HealthCap and Hadean Growth Fund Join Strong Investor Syndicate

STOCKHOLM, SWEDEN – July 22, 2025. Gesynta Pharma AB today announced it has raised an additional SEK 43 million in its Series B second closing, bringing the total Series B capital to SEK 347 million. New prominent investors, HealthCap and Hadean Growth Fund, joined the round, led by Innovestor Life Science. These additional funds will facilitate the preparation of the future Phase 3 program of vipoglanstat, a drug candidate aimed at revolutionizing the treatment of endometriosis, a disease affecting 190 million women globally. In conjunction with this capital infusion, Gesynta Pharma strengthens its board with the appointment of three new directors: Kristina Ekberg, partner at HealthCap, and independent directors Cristina Csimma and David Colpman.

Gesynta Pharma is preparing a Phase 2 clinical trial for vipoglanstat, a novel non-hormonal, non-opioid treatment for endometriosis. This chronic inflammatory disease, affecting one in ten women of reproductive age, can cause intense pain, impaired quality of life and infertility. Vipoglanstat targets mPGES-1, an enzyme found in endometriotic lesions (tissue similar to the lining of the uterus, growing outside the uterus), with preclinical data demonstrating marked reductions in both pain and lesions. The upcoming clinical proof-of-concept study will include approximately 190 patients in several countries across Europe.

“It is with great enthusiasm that we join this robust investor syndicate, dedicated to addressing a significant unmet medical need,” commented HealthCap partner Kristina Ekberg. “This investment reflects our strong confidence in Gesynta Pharma’s vision and its potential to deliver a genuine breakthrough in women’s health.”

Pekka Simula, Partner at Innovestor Life Science notes: “HealthCap’s participation is a tremendous addition to our Series B round. Their solid experience in the life science sector significantly enhances our syndicate, providing robust support for our ambitious goals.”

“This Series B second closing, reinforced by the commitment of new investors HealthCap and Hadean Growth Fund, accelerates our mission to deliver vipoglanstat as an innovative, non-hormonal solution for endometriosis patients,” remarks Roger Franklin, Chairman of Gesynta Pharma and partner at Hadean Ventures. “Furthermore, we are immensely pleased to welcome Cristina, David and Kristina to our board of directors. Their extensive expertise in drug development, business development, and venture capital will be instrumental in supporting our strategic growth, accelerating our efforts to deliver better treatments and enhance patient’s quality of life.”

For more information, please contact:

Patric Stenberg, CEO
Tel: + 46 (0)733 83 66 70
E-mail: patric.stenberg@gesynta.se

About Gesynta Pharma

Gesynta Pharma is a clinical-stage pharmaceutical company developing innovative treatments by targeting mPGES-1, a key enzyme in inflammatory processes. Gesynta Pharma's research originated at Karolinska Institutet in Sweden.

The lead compound, vipoglanstat, is being developed for the treatment of endometriosis - a painful chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to a severely reduced quality of life and current drug treatments are inadequate for many patients, partly due to troublesome side effects. Vipoglanstat is a non-hormonal, non-opioid, disease-modifying drug candidate that selectively inhibits mPGES-1; it has demonstrated a favorable safety profile and potent inhibition of mPGES-1 in Phase 1 and 2 clinical trials. A preclinical proof-of-concept study in an advanced disease model of endometriosis shows that vipoglanstat significantly reduces endometrial lesions and positively impacts pain-related parameters and well-being. A Phase 2 clinical trial in patients with endometriosis is expected to start in 2025.

A second drug candidate in the Gesynta Pharma portfolio, GS-073, is ready to enter clinical Phase 1 for the treatment of chronic inflammatory pain.

The company's main shareholders include several Nordic, European and US investors such as Hadean Ventures, Industrifonden, Innovestor Life Science, Linc, HealthCap, Foreground Capital, Amboy Street Ventures and other internationally renowned specialist investors. For more information, please visit www.gesynta.se.